Zafgen discontinues beloranib development

Zafgen Inc. (NASDAQ:ZFGN) sank $2.83 (42%) to $3.92 in early after-hours trading after it said it will discontinue development of subcutaneous beloranib ( ZGN-440) and focus instead on second-generation methionine aminopeptidase 2 (

Read the full 335 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE